- Pfizer Inc PFE and its partner, BioNTech SE BNTX, said that they developed their vaccine independently, refuting Moderna Inc's MRNA patent claims.
- In August, Moderna filed patent infringement lawsuits saying Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology critical in creating Moderna's mRNA COVID-19 vaccine.
- Pfizer called Moderna's lawsuit "revisionist history" and argued its patents "far exceed its actual contributions to the field."
- A Pfizer spokesperson said the company and BioNTech are confident in their intellectual property and will "vigorously defend" against Moderna's claims.
- Related: Moderna Shares Deep Dive After Lower COVID-19 Vaccine Sales Weigh On Q3 Sales, Profits.
- In its lawsuit, Moderna asked for an undisclosed amount of money damages from Pfizer COVID-19 vaccines sold since March.
- The companies argued that Moderna ignored the contributions of their scientists to foundational mRNA technology, as well as those of researchers at the U.S. government's National Institutes of Health.
- Alnylam Pharmaceuticals Inc ALNY and Arbutus Biopharma Corporation ABUS have lawsuits against Moderna regarding its COVID-19 vaccine.
- Price Action: MRNA shares are down 0.75% at $174.61 during the premarket session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.